Claims
- 1. A composition, comprising an aliphatic ammonium cation, wherein the aliphatic ammonium cation is a lipophilic, water-soluble aliphatic ammonium cation; and a phosphorylated inositol or a phosphorylated glyceric acid covalently bound to a sterol moiety.
- 2. The composition of claim 1, wherein inositol hexaphosphate or 2,3-DPG is covalently bound to the sterol moiety.
- 3. The composition of claim 1, wherein inositol hexaphosphate is covalently bound to the sterol moiety.
- 4. The composition of claim 1, wherein the aliphatic ammonium cation is a monoalkyl, dialkyl, trialkyl or tetraalkyl ammonium moiety.
- 5. The composition of claim 1, wherein the aliphatic ammonium cation is an N,N-dimethyl-cyclohexylammonium cation.
- 6. The composition of claim 1, wherein the aliphatic ammonium cation is a monoalkyl ammonium cation.
- 7. The composition of claim 1, wherein the aliphatic ammonium cation is a primary ammonium cation.
- 8. The composition of claim 1, wherein the sterol moiety is a cholesterol moiety.
- 9. The composition of claim 1, wherein inositol hexaphosphate is covalently bound to the sterol moiety; and the sterol moiety is a cholesterol moiety.
- 10. A compound represented by structure 1:
- 11. The compound of claim 10, wherein an instance of C+ that represents an ammonium ion selected independently for each occurrence from the group consisting of C1-C6 alkyl ammonium ions and C3-C6 cycloalkyl ammonium ions.
- 12. The compound of claim 10, wherein an instance of C+ that represents an ammonium ion selected independently for each occurrence from the group consisting of C3-C6 cycloalkyl ammonium ions.
- 13. The compound of claim 10, wherein an instance of C+ that represents an ammonium ion selected independently for each occurrence from the group consisting of cyclohexyl ammonium ions.
- 14. The compound of claim 10, wherein an instance of C+ that represents an ammonium ion is N,N-dimethyl-cyclohexylammonium.
- 15. The compound of claim 10, wherein An− is a ligand for the allosteric site of hemoglobin.
- 16. The compound of claim 10, wherein An− is a phosphorylated inositol or a phosphorylated glyceric acid.
- 17. The compound of claim 10, wherein An− is a phosphorylated inositol or a phosphorylated glyceric acid, wherein said phosphorylated inositol or phosphorylated glyceric acid is a ligand for the allosteric site of hemoglobin.
- 18. The compound of claim 10, wherein An− is IHP or 2,3-DPG.
- 19. The compound of claim 10, wherein an instance of C+ that represents an ammonium ion selected independently for each occurrence from the group consisting of C1-C6 alkyl ammonium ions and C3-C6 cycloalkyl ammonium ions; and An− is a ligand for the allosteric site of hemoglobin.
- 20. The compound of claim 10, wherein an instance of C+ that represents an ammonium ion selected independently for each occurrence from the group consisting of C1-C6 alkyl ammonium ions and C3-C6 cycloalkyl ammonium ions; M is a cholesterol moiety; and An− is a ligand for the allosteric site of hemoglobin.
- 21. The compound of claim 10, wherein an instance of C+ that represents an ammonium ion selected independently for each occurrence from the group consisting of C1-C6 alkyl ammonium ions and C3-C6 cycloalkyl ammonium ions; and An− is a phosphorylated inositol or a phosphorylated glyceric acid.
- 22. The compound of claim 10, wherein an instance of C+ that represents an ammonium ion selected independently for each occurrence from the group consisting of C1-C6 alkyl ammonium ions and C3-C6 cycloalkyl ammonium ions; M is a cholesterol moiety; and An− is a phosphorylated inositol or a phosphorylated glyceric acid.
- 23. The compound of claim 10, wherein an instance of C+ that represents an ammonium ion selected independently for each occurrence from the group consisting of C1-C6 alkyl ammonium ions and C3-C6 cycloalkyl ammonium ions; and An− is a phosphorylated inositol or a phosphorylated glyceric acid, wherein said phosphorylated inositol or phosphorylated glyceric acid is a ligand for the allosteric site of hemoglobin.
- 24. The compound of claim 10, wherein an instance of C+ that represents an ammonium ion selected independently for each occurrence from the group consisting of C1-C6 alkyl ammonium ions and C3-C6 cycloalkyl ammonium ions; M is a cholesterol moiety; and An− is a phosphorylated inositol or a phosphorylated glyceric acid, wherein said phosphorylated inositol or phosphorylated glyceric acid is a ligand for the allosteric site of hemoglobin.
- 25. The compound of claim 10, wherein an instance of C+ that represents an ammonium ion selected independently for each occurrence from the group consisting of C1-C6 alkyl ammonium ions and C3-C6 cycloalkyl ammonium ions; and An− is IHP or 2,3-DPG.
- 26. The compound of claim 10, wherein an instance of C+ that represents an ammonium ion selected independently for each occurrence from the group consisting of C1-C6 alkyl ammonium ions and C3-C6 cycloalkyl ammonium ions; M is a cholesterol moiety; and An− is IHP or 2,3-DPG.
- 27. The compound of claim 10, wherein an instance of C+ that represents an ammonium ion selected independently for each occurrence from the group consisting of C3-C6 cycloalkyl ammonium ions; and An− is a ligand for the allosteric site of hemoglobin.
- 28. The compound of claim 10, wherein an instance of C+ that represents an ammonium ion selected independently for each occurrence from the group consisting of C3-C6 cycloalkyl ammonium ions; M is a cholesterol moiety; and An− is a ligand for the allosteric site of hemoglobin.
- 29. The compound of claim 10, wherein an instance of C+ that represents an ammonium ion selected independently for each occurrence from the group consisting of C3-C6 cycloalkyl ammonium ions; and An− is a phosphorylated inositol or a phosphorylated glyceric acid.
- 30. The compound of claim 10, wherein an instance of C+ that represents an ammonium ion selected independently for each occurrence from the group consisting of C3-C6 cycloalkyl ammonium ions; M is a cholesterol moiety; and An− is a phosphorylated inositol or a phosphorylated glyceric acid.
- 31. The compound of claim 10, wherein an instance of C+ that represents an ammonium ion selected independently for each occurrence from the group consisting of C3-C6 cycloalkyl ammonium ions; and An− is a phosphorylated inositol or a phosphorylated glyceric acid, wherein said phosphorylated inositol or phosphorylated glyceric acid is a ligand for the allosteric site of hemoglobin.
- 32. The compound of claim 10, wherein an instance of C+ that represents an ammonium ion selected independently for each occurrence from the group consisting of C3-C6 cycloalkyl ammonium ions; M is a cholesterol moiety; and An− is a phosphorylated inositol or a phosphorylated glyceric acid, wherein said phosphorylated inositol or phosphorylated glyceric acid is a ligand for the allosteric site of hemoglobin.
- 33. The compound of claim 10, wherein an instance of C+ that represents an ammonium ion selected independently for each occurrence from the group consisting of C3-C6 cycloalkyl ammonium ions; and An− is IHP or 2,3-DPG.
- 34. The compound of claim 10, wherein an instance of C+ that represents an ammonium ion selected independently for each occurrence from the group consisting of C3-C6 cycloalkyl ammonium ions; M is a cholesterol moiety; and An− is IHP or 2,3-DPG.
- 35. The compound of claim 10, wherein an instance of C+ that represents an ammonium ion selected independently for each occurrence from the group consisting of cyclohexyl ammonium ions; and An− is a ligand for the allosteric site of hemoglobin.
- 36. The compound of claim 10, wherein an instance of C+ that represents an ammonium ion selected independently for each occurrence from the group consisting of cyclohexyl ammonium ions; M is a cholesterol moiety; and An− is a ligand for the allosteric site of hemoglobin.
- 37. The compound of claim 10, wherein an instance of C+ that represents an ammonium ion selected independently for each occurrence from the group consisting of cyclohexyl ammonium ions; and An− is a phosphorylated inositol or a phosphorylated glyceric acid.
- 38. The compound of claim 10, wherein an instance of C+ that represents an ammonium ion selected independently for each occurrence from the group consisting of cyclohexyl ammonium ions; M is a cholesterol moiety; and An− is a phosphorylated inositol or a phosphorylated glyceric acid.
- 39. The compound of claim 10, wherein an instance of C+ that represents an ammonium ion selected independently for each occurrence from the group consisting of cyclohexyl ammonium ions; and An− is a phosphorylated inositol or a phosphorylated glyceric acid, wherein said phosphorylated inositol or phosphorylated glyceric acid is a ligand for the allosteric site of hemoglobin.
- 40. The compound of claim 10, wherein an instance of C+ that represents an ammonium ion selected independently for each occurrence from the group consisting of cyclohexyl ammonium ions; M is a cholesterol moiety; and An− is a phosphorylated inositol or a phosphorylated glyceric acid, wherein said phosphorylated inositol or phosphorylated glyceric acid is a ligand for the allosteric site of hemoglobin.
- 41. The compound of claim 10, wherein an instance of C+ that represents an ammonium ion selected independently for each occurrence from the group consisting of cyclohexyl ammonium ions; and An− is IHP or 2,3-DPG.
- 42. The compound of claim 10, wherein an instance of C+ that represents an ammonium ion selected independently for each occurrence from the group consisting of cyclohexyl ammonium ions; M is a cholesterol moiety; and An− is IHP or 2,3-DPG.
- 43. The compound of claim 10, wherein C+ is a sodium ion; M is a cholesterol moiety; and An− is a ligand for the allosteric site of hemoglobin.
- 44. The compound of claim 10, wherein C+ is a sodium ion; M is a cholesterol moiety; and An− is a phosphorylated inositol or a phosphorylated glyceric acid, wherein said phosphorylated inositol or phosphorylated glyceric acid is a ligand for the allosteric site of hemoglobin.
- 45. The compound of claim 10, wherein C+ is a sodium ion; M is a cholesterol moiety; and An− is IHP or 2,3-DPG.
- 46. A pharmaceutical formulation, comprising a composition of claim 1 or a compound of claim 12; and a pharmaceutically acceptable excipient.
- 47. A method of enhancing oxygen delivery to a tissue or organ of a mammal, comprising the step of administering to a mammal a therapeutically effective amount of a composition of claim 1 or a compound of claim 10.
- 48. A method of enhancing oxygen delivery to a tissue or organ of a mammal, comprising the step of administering to a mammal red blood cells previously treated with a composition of claim 1 or a compound of claim 10.
- 49. A method of treating a mammal afflicted with anemia, coronary infarction, pulmonary disease, congestive heart failure, diabetes, myocardial infarction, stroke, peripheral vascular disease, intermittent claudication, circulatory shock, hemorrhagic shock, chronic hypoxia, altitude sickness, arteriosclerosis, respiratory alkalemia, metabolic alkalosis, sickle cell anemia, reduced lung capacity, gangrene, anaerobic infections, carbon monoxide poisoning, nitric oxide poisoning, or cyanide poisoning, comprising the step of administering to said mammal a therapeutically effective amount of a composition of claim 1 or a compound of claim 10.
- 50. A method of treating a mammal afflicted with anemia, coronary infarction, pulmonary disease, congestive heart failure, diabetes, myocardial infarction, stroke, peripheral vascular disease, intermittent claudication, circulatory shock, hemorrhagic shock, chronic hypoxia, altitude sickness, arteriosclerosis, respiratory alkalemia, metabolic alkalosis, sickle cell anemia, reduced lung capacity, gangrene, anaerobic infections, carbon monoxide poisoning, nitric oxide poisoning, or cyanide poisoning, comprising the step of administering to said mammal red blood cells previously treated with a composition of claim 1 or a compound of claim 10.
- 51. A method of improving the oxygen delivering capability of mammalian blood, comprising the step of adding to a volume of mammalian blood a composition of claim 1 or a compound of claim 10.
- 52. A method of incorporating a therapeutically useful substance into mammalian red blood cells, comprising the step of treating a sample of mammalian red blood cells with a composition of claim 1 or a compound of claim 10, wherein said composition or compound comprises said therapeutically useful substance.
RELATED APPLICATIONS
[0001] This application claims the benefit of priority to U.S. Provisional Patent Application serial No. 60/388,851, filed Jun. 14, 2002.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60388851 |
Jun 2002 |
US |